Presentation of endogenous viral proteins in association with major histocompatibility complex class II: On the role of intracellular compartmentalization, invariant chain and the TAP transporter system

被引:94
作者
Oxenius, A
Bachmann, MF
AshtonRickardt, PG
Tonegawa, S
Zinkernagel, RM
Hengartner, H
机构
[1] MIT,DEPT BIOL,CTR CANC RES,HOWARD HUGHES INST,CAMBRIDGE,MA
[2] UNIV CHICAGO,GWENN KNAPP CTR LUPUS & IMMUNOL RES,CHICAGO,IL 60637
关键词
class II; viral antigens; endogenous; invariant chain; TAP;
D O I
10.1002/eji.1830251230
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Major histocompatibility complex (MHC) class II-associated antigen presentation is mainly linked to processing of exogenous antigens upon cellular uptake by endocytosis, but has also been observed for endogenously sythesized antigens. We have studied the MHC class II-associated presentation of the endogenously synthesized membrane associated glycoprotein (GP) and the cytosolic nucleoprotein (NP) of lymphocytic choriomeningitis virus (LCMV) in professional antigen presenting cells (APC) of mice. Since LCMV is a noncytopathic virus and minimally affects cellular protein synthesis, it is a convenient virus for the study of antigen presentation. In contrast, most other studies assessing class II-associated presentation of endogeneously synthesized viral antigens used cytolytic viruses such as vaccinia, measles and influenza virus, which drastically interfere with host cell functions. In addition, most studies were performed using non-professional APC. We found that class II-associated presentation of endogenously synthesized membrane associated LCMV-GP was efficient and could not be inhibited by chloroquine or leupeptin. Neither the transporter associated with professing (TAP) system nor the invariant chain (Ii) were significantly involved in this process. In contrast, MHC class II-associated presentation of endogenously synthesized cytosolic LCMV-NP was not observed even in Ii-deficient APC. Thus, MHC class II loading of endogenously synthesized LCMV-GP apparently does not require processing in acidic endosomal compartments as defined by chloroquine and leupeptin insensitivity Furthermore, although the TAP molecules transport peptides of up to 15 amino acids in length, which potentially could bind to MHC class II molecules in the endoplasmic reticulum, such a process apparently does not occur for either the glycoprotein or the nucleoprotein. Therefore, the subcellular localization of an endogenously synthesized protein influences crucially whether or not MHC class II loading can occur independently of the acidic compartments usually involved in MHC class II loading.
引用
收藏
页码:3402 / 3411
页数:10
相关论文
共 75 条
  • [1] TRANSIENT ACCUMULATION OF NEW CLASS-II MHC MOLECULES IN A NOVEL ENDOCYTIC COMPARTMENT IN B-LYMPHOCYTES
    AMIGORENA, S
    DRAKE, JR
    WEBSTER, P
    MELLMAN, I
    [J]. NATURE, 1994, 369 (6476) : 113 - 120
  • [2] BINDING OF IMMUNOGENIC PEPTIDES TO IA HISTOCOMPATIBILITY MOLECULES
    BABBITT, BP
    ALLEN, PM
    MATSUEDA, G
    HABER, E
    UNANUE, ER
    [J]. NATURE, 1985, 317 (6035) : 359 - 361
  • [3] BACHMANN MF, 1994, EUR J IMMUNOL, V24, P2128
  • [4] BACIK I, 1994, J IMMUNOL, V152, P381
  • [5] MHC CLASS-II-ASSOCIATED INVARIANT CHAIN CONTAINS A SORTING SIGNAL FOR ENDOSOMAL COMPARTMENTS
    BAKKE, O
    DOBBERSTEIN, B
    [J]. CELL, 1990, 63 (04) : 707 - 716
  • [6] SELECTIVE KILLING OF HEPATITIS-B ENVELOPE ANTIGEN-SPECIFIC B-CELLS BY CLASS-I-RESTRICTED, EXOGENOUS ANTIGEN-SPECIFIC LYMPHOCYTES-T
    BARNABA, V
    FRANCO, A
    ALBERTI, A
    BENVENUTO, R
    BALSANO, F
    [J]. NATURE, 1990, 345 (6272) : 258 - 260
  • [7] CLASS DISCRIMINATION IN THE WORLD OF IMMUNOLOGY
    BEVAN, MJ
    [J]. NATURE, 1987, 325 (6101) : 192 - 194
  • [8] BIJLMAKERS MJ, 1994, EMBO, V13, P2669
  • [9] DEFECTIVE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II ASSEMBLY, TRANSPORT, PEPTIDE ACQUISITION, AND CD4+ T-CELL SELECTION IN MICE LACKING INVARIANT CHAIN EXPRESSION
    BIKOFF, EK
    HUANG, LY
    EPISKOPOU, V
    VANMEERWIJK, J
    GERMAIN, RN
    ROBERTSON, EJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (06) : 1699 - 1712
  • [10] BIKOFF EK, 1992, J IMMUNOL, V149, P1